Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
June 20, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
The reiteration of an Overweight rating by Morgan Stanley's analyst indicates a positive outlook for Silence Therapeutics. This could lead to increased investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100